MetaCap

Harmony Biosciences Holdings Inc. (HRMY)

NASDAQ: HRMYHealth CareBiotechnology: Pharmaceutical PreparationsUSD

32.59-0.39 (-1.18%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

HRMY stock chart

Technical analysis

Key statistics

All statistics
52-week range
25.90 – 43.49
Day range
32.51 – 33.43
Volume / Avg
582.64K / 1.01M
Beta
—

52-week range

$25.90$43.49

HRMY stock today

Harmony Biosciences (HRMY) closed at $32.59 on Nov 20, down 1.18% (-$0.39), versus the S&P 500's 3.70% decline. At this level, HRMY sits in the middle of its 52-week range of $25.90 to $43.49: 25.1% below the high, set on Sep 3, 2026 and 25.8% above the low. HRMY is down 12.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.0%.

Harmony Biosciences trades at 10.8x its trailing twelve-month earnings per share of $3.02. Its forward P/E of 5.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Harmony Biosciences

Company profile

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD).

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Jeffrey M. Dayno M.D.
Headquarters
Plymouth Meeting, PA
Employees
293
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Harmony Biosciences generated $868.5 million in revenue, up 21.5% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $158.7 million (+9.1% year over year), for a net margin of 18.3% versus a median of 20.4% in the prior 5 years. Gross margin was 77.2% (down from 78.1%) and operating margin 24.0%.

Harmony Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$868.45M$714.73M$582.02M$437.86M$305.44M
Growth+21.51%+22.80%+32.93%+43.35%+91.21%
Net income$158.69M$145.49M$128.85M$181.47M$34.60M
EPS (diluted)$2.71$2.51$2.13$2.97$0.58

Analyst forecast

Forecast

Consensus (12 analysts)

buy

Avg. price target

$48.08+47.53%

  • Strong buy 2
  • Buy 6
  • Hold 3
  • Sell 0
  • Strong sell 1

Target range

Low $32.00High $70.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.87 vs $1.00
Surprise
-13.00%

HRMY news

All HRMY news

Harmony Biosciences peers

Health Care sector
HRMY peer companies
CompanyPrice% ChgMarket capCompare
AUPHAurinia Pharmaceuticals Inc14.70-1.28%$1.97Bvs HRMY
TRVITrevi Therapeutics Inc.13.35-2.70%$1.90Bvs HRMY
BHVNBiohaven Ltd.12.39-9.23%$1.87Bvs HRMY
IMNMImmunome Inc.15.69-5.54%$1.85Bvs HRMY
VERAVera Therapeutics Inc. Class A25.45-4.86%$1.84Bvs HRMY
SEPNSepterna Inc.38.61-1.51%$1.84Bvs HRMY
MRVIMaravai LifeSciences Holdings Inc. Class A6.98-2.92%$1.81Bvs HRMY
ZYMEZymeworks Inc.26.14-2.68%$1.81Bvs HRMY

Indexes, lists and sector

Harmony Biosciences stock FAQ

What is Harmony Biosciences's stock price today?

HRMY last traded at $32.59 as of Nov 20, 4:00 PM EST, down 1.18% on the day. Prices are delayed at least 15 minutes.

What is HRMY's P/E ratio?

HRMY trades at a trailing P/E ratio of 10.79 and a forward P/E of 5.37.

Who is Harmony Biosciences's CEO?

Dr. Jeffrey M. Dayno M.D. is the chief executive officer of Harmony Biosciences Holdings Inc., which has about 293 employees.

What is the HRMY 52-week high?

The 52-week high for HRMY is $43.49 and the 52-week low is $25.90. The stock is currently 25.1% below its high.

Compare HRMY